Categories: Wire Stories

IDEMIA Partners With JAC to Successfully Test Frictionless Biometric Access Technology at Level5 Stadium in Japan

MorphoWave Compact biometric authentication technology was showcased during the final match of the J2 League. The proof of concept included ticketless/handsfree admission for pre-registered customers and food and beverage collection and biometric verification at the pickup counter.

SINGAPORE–(BUSINESS WIRE)–IDEMIA, the global leader in Augmented Identity and Japan Aerospace Corporation (JAC) partnered to demonstrate a proof of concept with MorphoWave™ Compact, a unique award-winning access control biometric device.

A first in Japan, the biometric access technology was successfully tested at Level5 stadium in Fukuoka during the final match of the J2 League between Avispa Fukuoka and Kagoshima United Football Club at the end of 2019.

MorphoWave™ Compact enables four fingerprints to be read in less than one second by a wave of the hand across the device. This biometric access solution enables the stadium to combine speed and convenience with a high level of security within its high traffic environment.

Two use cases were tested during the game:

  1. Ticketless / handsfree admission: pre-registered customers were able to enter the stadium by biometric authentication without a physical ticket
  2. Verifying the identity of the customer by a wave of the hand on the biometric terminal at the food and beverage pick-up counter.

“Our goal is to enable frictionless access everywhere without compromising security,” said Nobuyoshi Nezu, Managing Director and Vice President of Sales for IDEMIA Japan. “IDEMIA has developed MorphoWave Compact, a touchless fingerprint device that enables this, by combining a high level of biometric security with a unique user experience, convenience and speed, which is what environments like a stadium need. We are excited to partner with Japan Aerospace Corporation on this very promising case and look forward to a full rollout of our MorphoWavedevices at Level5 Stadium.”

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters.

We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With 13,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter

Contacts

Press

REDHILL Communications

Uma Kanapathy

Email: idemia@redhill.asia

Alex

Recent Posts

HKU engineering researchers develop revolutionary diamond fabrication technology

HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - A research team…

12 minutes ago

Agilis Robotics completes world’s first robot-assisted bladder tumour resection in clinical trial

HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - Agilis Robotics has…

1 hour ago

LOFTER GROUP Awarded 12 Honors at PropertyGuru Asia Property Awards, Recognized as Best Boutique Developer (Hong Kong and Macau)

UPPER PRINCE Triumphs as Best Connectivity Condo Development in Asia HONG KONG SAR - Media…

1 hour ago

Delta Dunia Group Delivers Steady 9M 2024 Results with Transformative Milestones to Fuel Long-Term Growth

Despite significant challenges posed by extreme weather conditions in Indonesia and Australia, Delta Dunia Group…

2 hours ago

Exchange Plastic for Rewards with 1win and Recycledge

IBADAN, NIGERIA - Media OutReach Newswire – 20 December 2024 - Leading global iGaming brand…

2 hours ago

AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth points for performance

HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - AIM Vaccine (06660.HK)…

5 hours ago